369
Views
14
CrossRef citations to date
0
Altmetric
Review

Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine

, , , , , , , , , , & show all

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Articles from other publishers (13)

Beibei Zhang, Hongyan Mao, Hongjuan Zhu, Jingxia Guo, Paul Zhou & Zhenghai Ma. (2023) Response to HIV-1 gp160-carrying recombinant virus HSV-1 and HIV-1 VLP combined vaccine in BALB/c mice. Frontiers in Microbiology 14.
Crossref
Barbara Ensoli, Sonia Moretti, Alessandra Borsetti, Maria Teresa Maggiorella, Stefano Buttò, Orietta Picconi, Antonella Tripiciano, Cecilia Sgadari, Paolo Monini & Aurelio Cafaro. (2021) New insights into pathogenesis point to HIV-1 Tat as a key vaccine target. Archives of Virology 166:11, pages 2955-2974.
Crossref
Zahra Falahati, Atiyeh Mahdavi & Leila Hassani. (2020) Physicochemical studies on the structural stability of the HIV-1 vaccine candidate recombinant Tat protein. International Journal of Biological Macromolecules 164, pages 403-414.
Crossref
Aurelio Cafaro, Antonella Tripiciano, Orietta Picconi, Cecilia Sgadari, Sonia Moretti, Stefano Buttò, Paolo Monini & Barbara Ensoli. (2019) Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease. Vaccines 7:3, pages 99.
Crossref
Marc H V Van RegenmortelMarc H V Van Regenmortel. 2019. HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design. HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design 229 248 .
Edith Hanna, Mohammed Dany, Ossama Abbas, Firas Kreidieh & Mazen Kurban. (2018) Updates on the use of vaccines in dermatological conditions. Indian Journal of Dermatology, Venereology and Leprology 84:4, pages 388.
Crossref
Arunachalam Muthuraman, Narahari Rishitha & Seema Mehdi. 2018. Design of Nanostructures for Theranostics Applications. Design of Nanostructures for Theranostics Applications 529 562 .
Ehsan Ollah Jazaeri, Atiyeh Mahdavi & Asghar Abdoli. (2017) Formulation of chitosan with the polyepitope HIV-1 protein candidate vaccine efficiently boosts cellular immune responses in mice. Pathogens and Disease 75:8.
Crossref
Jessica L Prodger, Jun Lai, Steven J Reynolds, Jeanne C Keruly, Richard D Moore, Jingo Kasule, Taddeo Kityamuweesi, Paul Buule, David Serwadda, Martha Nason, Adam A Capoferri, Stephen F Porcella, Robert F Siliciano, Andrew D Redd, Janet D Siliciano & Thomas C Quinn. (2017) Reduced Frequency of Cells Latently Infected With Replication-Competent Human Immunodeficiency Virus-1 in Virally Suppressed Individuals Living in Rakai, Uganda. Clinical Infectious Diseases 65:8, pages 1308-1315.
Crossref
Manutea Serrero, Rémi Planès & Elmostafa Bahraoui. (2017) PKC-δ isoform plays a crucial role in Tat-TLR4 signalling pathway to activate NF-κB and CXCL8 production. Scientific Reports 7:1.
Crossref
Barbara Ensoli, Maphoshane Nchabeleng, Fabrizio Ensoli, Antonella Tripiciano, Stefania Bellino, Orietta Picconi, Cecilia Sgadari, Olimpia Longo, Lara Tavoschi, Daniel Joffe, Aurelio Cafaro, Vittorio Francavilla, Sonia Moretti, Maria Rosaria Pavone Cossut, Barbara Collacchi, Angela Arancio, Giovanni Paniccia, Anna Casabianca, Mauro Magnani, Stefano Buttò, Elise Levendal, John Velaphi Ndimande, Bennett Asia, Yogan Pillay, Enrico Garaci & Paolo Monini. (2016) HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. Retrovirology 13:1.
Crossref
Aurelio Cafaro, Giovanni Piccaro, Giuseppe Altavilla, Vincenzo Gigantino, Giuseppe Matarese, Erika Olivieri, Flavia Ferrantelli, Barbara Ensoli & Carla Palma. (2016) HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology. BMC Infectious Diseases 16:1.
Crossref
Glenda E Gray, Fatima Laher, Erica Lazarus, Barbara Ensoli & Lawrence Corey. (2016) Approaches to preventative and therapeutic HIV vaccines. Current Opinion in Virology 17, pages 104-109.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.